Diabetes, Vol 46, Issue 6 1062-1068, Copyright © 1997 by American Diabetes Association

ARTICLES

Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs

N Vionnet, EH Hani, S Lesage, A Philippi, J Hager, M Varret, M Stoffel, Y Tanizawa, KC Chiu, B Glaser, MA Permutt, P Passa, F Demenais and P Froguel
Centre National Recherche Scientifique, Institut Pasteur de Lille, France. n.vionnet@xenope.univ-lille2.fr

As part of an ongoing search for susceptibility loci for NIDDM, we tested 19 genes whose products are implicated in insulin secretion or action for linkage with NIDDM. Loci included the G-protein-coupled inwardly rectifying potassium channels expressed in beta-cells (KCNJ3 and KCNJ7), glucagon (GCG), glucokinase regulatory protein (GCKR), glucagon-like peptide I receptor (GLP1R), LIM/homeodomain islet-1 (ISL1), caudal-type homeodomain 3 (CDX3), proprotein convertase 2 (PCSK2), cholecystokinin B receptor (CCKBR), hexokinase 1 (HK1), hexokinase 2 (HK2), mitochondrial FAD-glycerophosphate dehydrogenase (GPD2), liver and muscle forms of pyruvate kinase (PKL, PKM), fatty acid-binding protein 2 (FABP2), hepatic phosphofructokinase (PFKL), protein serine/threonine phosphatase 1 beta (PPP1CB), and low-density lipoprotein receptor (LDLR). Additionally, we tested the histidine-rich calcium locus (HRC) on chromosome 19q. All regions were tested for linkage with microsatellite markers in 751 individuals from 172 families with at least two patients with overt NIDDM (according to World Health Organization criteria) in the sibship, using nonparametric methods. These 172 families comprise 352 possible affected sib pairs with overt NIDDM or 621 possible affected sib pairs defined as having a fasting plasma glucose value of >6.1 mmol/l or a glucose value of >7.8 mmol/l 2 h after oral glucose load. No evidence for linkage was found with any of the 19 candidate genes and NIDDM in our population by nonparametric methods, suggesting that those genes are not major contributors to the pathogenesis of NIDDM. However, some evidence for suggestive linkage was found between a more severe form of NIDDM, defined as overt NIDDM diagnosed before 45 years of age, and the CCKBR locus (11p15.4; P = 0.004). Analyses of six additional markers spanning 27 cM on chromosome 11p confirmed the suggestive linkage in this region. Whether an NIDDM susceptibility gene lies on chromosome 11p in our population must be determined by further analyses.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				P. Holm, B. Rydlander, H. Luthman, and I. Kockum Interaction and Association Analysis of a Type 1 Diabetes Susceptibility Locus on Chromosome 5q11-q13 and the 7q32 Chromosomal Region in Scandinavian Families Diabetes, June 1, 2004; 53(6): 1584 - 1591. [Abstract] [Full Text] [PDF]

				L. J. Martin, A. G. Comuzzie, S. Dupont, N. Vionnet, C. Dina, S. Gallina, M. Houari, J. Blangero, and P. Froguel A Quantitative Trait Locus Influencing Type 2 Diabetes Susceptibility Maps to a Region on 5q in an Extended French Family Diabetes, December 1, 2002; 51(12): 3568 - 3572. [Abstract] [Full Text] [PDF]

				E. P. Weiss, M. D. Brown, A. R. Shuldiner, and J. M. Hagberg Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects Physiol Genomics, September 3, 2002; 10(3): 145 - 157. [Abstract] [Full Text] [PDF]

				T. Rice, Y. C. Chagnon, L. Perusse, I. B. Borecki, O. Ukkola, T. Rankinen, J. Gagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, et al. A Genomewide Linkage Scan for Abdominal Subcutaneous and Visceral Fat in Black and White Families: The HERITAGE Family Study Diabetes, March 1, 2002; 51(3): 848 - 855. [Abstract] [Full Text] [PDF]

				E. D. Slosberg, U. J. Desai, B. Fanelli, I. St. Denny, S. Connelly, M. Kaleko, B. R. Boettcher, and S. L. Caplan Treatment of Type 2 Diabetes by Adenoviral-Mediated Overexpression of the Glucokinase Regulatory Protein Diabetes, August 1, 2001; 50(8): 1813 - 1820. [Abstract] [Full Text] [PDF]

				J. R. Galluzzi, L. A. Cupples, J. B. Meigs, P. W.F. Wilson, E. J. Schaefer, and J. M. Ordovas Association of the Ala54-thr Polymorphism in the Intestinal Fatty Acid-Binding Protein With 2-h Postchallenge Insulin Levels in the Framingham Offspring Study Diabetes Care, July 1, 2001; 24(7): 1161 - 1166. [Abstract] [Full Text] [PDF]

				G. Emilien, M. Ponchon, C. Caldas, O. Isacson, and J.-M. Maloteaux Impact of genomics on drug discovery and clinical medicine QJM, July 1, 2000; 93(7): 391 - 423. [Abstract] [Full Text] [PDF]

				J. Grimsby, J. W. Coffey, M. T. Dvorozniak, J. Magram, G. Li, F. M. Matschinsky, C. Shiota, S. Kaur, M. A. Magnuson, and J. F. Grippo Characterization of Glucokinase Regulatory Protein-deficient Mice J. Biol. Chem., March 10, 2000; 275(11): 7826 - 7831. [Abstract] [Full Text] [PDF]

				D. Farrelly, K. S. Brown, A. Tieman, J. Ren, S. A. Lira, D. Hagan, R. Gregg, K. A. Mookhtiar, and N. Hariharan Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation PNAS, December 7, 1999; 96(25): 14511 - 14516. [Abstract] [Full Text] [PDF]